MoonLake Immunotherapeutics Balance Sheet Health
Financial Health criteria checks 6/6
MoonLake Immunotherapeutics has a total shareholder equity of $513.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $526.5M and $13.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$511.01m |
| Equity | US$513.49m |
| Total liabilities | US$13.05m |
| Total assets | US$526.54m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: MLTX N's short term assets ($514.2M) exceed its short term liabilities ($10.0M).
Long Term Liabilities: MLTX N's short term assets ($514.2M) exceed its long term liabilities ($3.1M).
Debt to Equity History and Analysis
Debt Level: MLTX N is debt free.
Reducing Debt: MLTX N had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MLTX N has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MLTX N has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 7.1% each year